You've reached the limit for free Overall Ranking scores. For more information, request a demo.
See CSRHub in Action
You have a total of 10 free searches available.
| Low 0-29 | 30-39 | 40-49 | 50-59 | 60-79 | 80-100 High |
Targacept, Inc. is a biopharmaceutical company engaged in the design, discovery and development of NNR Therapeutics, a class of drugs for the treatment of multiple diseases and disorders of the central nervous system. The company’s NNR Therapeutics selectively target neuronal nicotinic receptors, or NNRs. NNRs are found on nerve cells throughout the nervous system and serve as key regulators of nervous system activity. The company has a clinical-stage product pipeline and multiple preclinical product candidates. Its most advanced product candidates are in development for major depressive disorder, attention deficit/hyperactivity disorder, Alzheimer’s disease and cognitive dysfunction in schizophrenia.
Changed name to Catalyst Biosciences, Inc. from Targacept, Inc., 8/23/2023.
| Ticker: | CBIO |
| ISIN: | US14888D2080 |
| Address: |
200 East First Street, Suite 300 |
| Winston Salem, NC, 27101, USA | |
| Website: | Catalyst Biosciences, Inc. |
| Phone #: | 337-948-3033 |
| ESG Web Area: | Subscribers Only ? |
| Industry: | Pharmaceutical & Medicine Manufacturing |
We considered many names for our site—in fact we spent our first year and a half under a different name—EkoHub. We liked “Eko” — coming from the Greek word Oikos, related to economy, ecology, and “home” or social concerns. From the beginning, we believed the word “Hub” reflected our desire to be at the center of the sustainability area, providing knowledge, harmony, and consensus among the hundreds of experts judging the ESG performance of companies.